GlassScriptPhysician profile
Heather Gillespie
NPI 1346380748
$3,517.12
in general payments reported to CMS, 2019-2025
18 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $56.35 · 2021: $292 · 2022: $155 · 2023: $929 · 2024: $1,106 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,455.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $842.22 | 2019-2025 | Tepezza, Tavneos, Otezla |
| Aurinia Pharma U.S., INC. | $657.68 | 2023-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $270.86 | 2023-2025 | Saphnelo |
| Horizon Therapeutics Plc | $245.41 | 2019-2023 | Tepezza |
| Pfizer INC. | $224.01 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.99 | 2021 | |
| Abbvie INC. | $198.00 | 2020-2022 | |
| Janssen Biotech, INC. | $174.12 | 2020-2024 | Simponi Aria, Tremfya |
| Janssen Scientific Affairs, LLC | $149.99 | 2024 | Tremfya |
| Glaxosmithkline, LLC. | $125.00 | 2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $119.55 | 2019 | |
| Genentech USA, INC. | $99.99 | 2019 | |
| Calliditas Therapeutics US INC. | $56.60 | 2024 | |
| Celgene Corporation | $34.13 | 2019 | |
| Ucb, INC. | $28.92 | 2023 | Cimzia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $25.44 | 2024 | Eylea Hd |
| Mindera Corp | $24.81 | 2025 | |
| Baxter Healthcare | $20.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.